Bioactive versus bare platinum coils in the treatment of intracranial aneurysms: The MAPS (Matrix and Platinum Science) trial

Cameron G. McDougall, S. Claiborne Johnston, A. Gholkar, S. L. Barnwell, J. C. Vazquez Suarez, J. Massó Romero, J. C. Chaloupka, A. Bonafe, A. K. Wakhloo, D. Tampieri, C. F. Dowd, A. J. Fox, S. J. Imm, K. Carroll, A. S. Turk

Research output: Contribution to journalArticle

65 Scopus citations

Abstract

BACKGROUND AND PURPOSE: The ability of polymer-modified coils to promote stable aneurysm occlusion after endovascular treatment is not well-documented. Angiographic aneurysm recurrence is widely used as a surrogate for treatment failure, but studies documenting the correlation of angiographic recurrence with clinical failure are limited. This trial compares the effectiveness of Matrix2 polyglycolic/polylactic acid biopolymer-modified coils with bare metal coils and correlates the angiographic findings with clinical failure (ie, target aneurysm recurrence), a composite end point that includes any incident of posttreatment aneurysm rupture, retreatment, or unexplained death. MATERIALSANDMETHODS: This was a multicenter randomized noninferiority trial with blinded end point adjudication.Weenrolled 626 patients, divided between Matrix2 and bare metal coil groups. The primary outcome was target aneurysm recurrence at 12 ± 3 months. RESULTS: At 455 days, at least 1 target aneurysm recurrence event had occurred in 14.6% of patients treated with bare metal coils and 13.3% of Matrix2 (P=.76, log-rank test) patients; 92.8% of target aneurysm recurrence events were re-interventions for aneurysms that had not bled after treatment, and 5.8% of target aneurysm recurrence events resulted from hemorrhage or rehemorrhage, with or without retreatment. Symptomatic re-intervention occurred in only 4 (0.6%) patients. At 455 days, 95.8% of patients with unruptured aneurysms and 90.4% of those with ruptured aneurysms were independent (mRS ≤ 2). Target aneurysm recurrence was associated with incomplete initial angiographic aneurysm obliteration, presentation with rupture, and a larger aneurysmal dome and neck size. CONCLUSIONS: Tested Matrix2 coils were not inferior to bare metal coils. Endovascular coiling of intracranial aneurysms was safe, and the rate of technical success was high. Target aneurysm recurrence is a promising clinical outcome measure that correlates well with established angiographic measurements.

Original languageEnglish (US)
Pages (from-to)935-942
Number of pages8
JournalAmerican Journal of Neuroradiology
Volume39
Issue number5
DOIs
StatePublished - May 2014

    Fingerprint

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Clinical Neurology

Cite this

McDougall, C. G., Claiborne Johnston, S., Gholkar, A., Barnwell, S. L., Vazquez Suarez, J. C., Massó Romero, J., Chaloupka, J. C., Bonafe, A., Wakhloo, A. K., Tampieri, D., Dowd, C. F., Fox, A. J., Imm, S. J., Carroll, K., & Turk, A. S. (2014). Bioactive versus bare platinum coils in the treatment of intracranial aneurysms: The MAPS (Matrix and Platinum Science) trial. American Journal of Neuroradiology, 39(5), 935-942. https://doi.org/10.3174/ajnr.A3857